Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Escitalopram Clear all
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jun 7, 2026, 4:27 AM EDT
Withdrawn Phase 4 Interventional

The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives

NCT02028026
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety, Comorbidity
Interventions
Vilazodone, Citalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Jun 7, 2026, 4:27 AM EDT
Terminated Phase 3 Interventional Results available

Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer

NCT00387348
View directory record Official record
Conditions
Colorectal Cancer, Depression, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Fatigue, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer
Interventions
escitalopram oxalate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2012 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 4 Interventional

Escitalopram Treatment of Patients With Agitated Dementia

NCT00260624
View directory record Official record
Conditions
Alzheimer's Disease, Psychomotor Agitation
Interventions
Escitalopram (Lexapro)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
61 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Fairport, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Jun 7, 2026, 4:27 AM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 7, 2026, 4:27 AM EDT
Terminated Phase 2 Interventional Results available

Adherence to Antidepressant Treatment in Subjects With Depression

NCT03388164
View directory record Official record
Conditions
Depression
Interventions
Escitalopram + RT2CK17, Escitalopram + Placebo
Drug
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms

NCT01189812
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Borderline Personality Disorder
Interventions
Lithium Carbonate, Placebo, Citalopram
Drug
Lead sponsor
Columbia Northwest Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
San Diego, California • Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Characteristics of Sleep Patterns in Young Adults With and Without Insomnia

NCT00177216
View directory record Official record
Conditions
Sleep Disorders
Interventions
Zolpidem, Escitalopram, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
20 Years to 50 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Jun 7, 2026, 4:27 AM EDT
Not listed Phase 1 Interventional

Serotonergic Modulation of Motor Function in Subacute and Chronic SCI

NCT01788969
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Lexapro, Placebo
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 2Phase 3 Interventional

Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)

NCT00018902
View directory record Official record
Conditions
Depression
Interventions
Fluoxetine, Venlafaxine, Cognitive Behavioral Therapy (CBT), Citalopram
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 18 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 4 Interventional

Biomarkers for Outcomes In Late-life Depression (BOLD)

NCT01082237
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
62 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 4 Interventional Results available

Drug Therapy for Generalized Anxiety Disorder Among the Elderly

NCT00105586
View directory record Official record
Conditions
Anxiety Disorders, Generalized Anxiety Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2017 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

Escitalopram Treatment of Night Eating Syndrome

NCT00636649
View directory record Official record
Conditions
Night Eating Syndrome
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
St Louis, Missouri • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Jun 7, 2026, 4:27 AM EDT
Terminated Phase 4 Interventional Results available

Antidepressant Response in Older Adults With Comorbid PTSD and MDD

NCT04697693
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Major Depressive Disorder
Interventions
Escitalopram, Duloxetine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 105 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Jun 7, 2026, 4:27 AM EDT
Withdrawn Phase 4 Interventional

Anxiety and Depression in Epilepsy: A Pilot Treatment Study

NCT03522987
View directory record Official record
Conditions
Anxiety, Depression, Epilepsy
Interventions
Escitalopram 10mg
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Modafinil - Escitalopram Study for Cocaine Dependence

NCT01601730
View directory record Official record
Conditions
Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Substance Abuse
Interventions
Modafinil and Escitalopram, Placebo, Modafinil, Escitalopram
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Jun 7, 2026, 4:27 AM EDT
Recruiting Phase 2Phase 3 Interventional

Home Transcutaneous Electrical Acustimulation (TEA)

NCT05519683
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
TEA, Lexapro
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Enhanced Motor Recovery Using Serotonergic Agents in Stroke

NCT01751854
View directory record Official record
Conditions
Patients With Chronic Stroke
Interventions
SSRI, Placebo
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 27, 2016 · Synced Jun 7, 2026, 4:27 AM EDT
Completed No phase listed Observational Results available

STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse

NCT00369746
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
citalopram
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jun 7, 2026, 4:27 AM EDT
Active, not recruiting Phase 3 Interventional

Escitalopram for Agitation in Alzheimer's Disease

NCT03108846
View directory record Official record
Conditions
Dementia
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years to 109 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
22
States / cities
Sun City, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

NCT01364649
View directory record Official record
Conditions
Treatment Outcome
Interventions
Vortioxetine, Escitalopram, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
53
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Jun 7, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

Drug Therapy to Treat Minor Depression

NCT00048815
View directory record Official record
Conditions
Depression
Interventions
Citalopram, St. John's Wort, Placebos
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Jun 7, 2026, 4:27 AM EDT